Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico.
Mult Scler J Exp Transl Clin
; 10(3): 20552173241260156, 2024.
Article
em En
| MEDLINE
| ID: mdl-39091340
ABSTRACT
Background:
Cladribine shows efficacy in multiple sclerosis (MS), but Latin American (LATAM) real-world data is limited, despite potential sociodemographic variations.Objective:
Investigate baseline characteristics and clinical response in highly active MS patients in Mexico, identifying predictors of early treatment response.Method:
A multicenter cohort study analyzed retrospective data from individuals with "highly active" MS in the Cladribine Patient Support Program across 11 Mexican clinics. Criteria included one-year prior treatment with another disease-modifying treatment and recent relapse with specific MRI findings. Primary outcomes focused on achieving NEDA-3 status after 12 months.Results:
In the follow-up, 67.5% maintained NEDA-3 status. Baseline EDSS scores decreased significantly from 1.50 to 1.00 (p = 0.011), with no confirmed disability worsening. No significant differences were observed between NEDA-3 achievers and non-achievers in demographic and clinical variables. No severe adverse events were reported.Conclusion:
Cladribine showed early and effective control of active MS in Mexican patients, demonstrating a secure profile with minimal adverse events. This study provides valuable real-world evidence in the LATAM context.
Texto completo:
1
Bases de dados:
MEDLINE
País/Região como assunto:
Mexico
Idioma:
En
Revista:
Mult Scler J Exp Transl Clin
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
México